204 related articles for article (PubMed ID: 18834634)
1. Stability of an organometallic ruthenium-ubiquitin adduct in the presence of glutathione: relevance to antitumour activity.
Hartinger CG; Casini A; Duhot C; Tsybin YO; Messori L; Dyson PJ
J Inorg Biochem; 2008 Dec; 102(12):2136-41. PubMed ID: 18834634
[TBL] [Abstract][Full Text] [Related]
2. Competition between glutathione and guanine for a ruthenium(II) arene anticancer complex: detection of a sulfenato intermediate.
Wang F; Xu J; Habtemariam A; Bella J; Sadler PJ
J Am Chem Soc; 2005 Dec; 127(50):17734-43. PubMed ID: 16351102
[TBL] [Abstract][Full Text] [Related]
3. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
[TBL] [Abstract][Full Text] [Related]
4. Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(eta6-p-cymene)Cl2(pta)].
Scolaro C; Hartinger CG; Allardyce CS; Keppler BK; Dyson PJ
J Inorg Biochem; 2008 Sep; 102(9):1743-8. PubMed ID: 18582946
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.
Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ
J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028
[TBL] [Abstract][Full Text] [Related]
6. Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action.
Casini A; Karotki A; Gabbiani C; Rugi F; Vašák M; Messori L; Dyson PJ
Metallomics; 2009 Sep; 1(5):434-41. PubMed ID: 21305148
[TBL] [Abstract][Full Text] [Related]
7. Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage.
Furrer MA; Schmitt F; Wiederkehr M; Juillerat-Jeanneret L; Therrien B
Dalton Trans; 2012 Jun; 41(24):7201-11. PubMed ID: 22506276
[TBL] [Abstract][Full Text] [Related]
8. Competition between glutathione and DNA oligonucleotides for ruthenium(II) arene anticancer complexes.
Wang F; Xu J; Wu K; Weidt SK; Mackay CL; Langridge-Smith PR; Sadler PJ
Dalton Trans; 2013 Mar; 42(9):3188-95. PubMed ID: 23076358
[TBL] [Abstract][Full Text] [Related]
9. Metabolization of [Ru(eta(6)-C (6)H (5)CF (3))(pta)Cl (2)]: a cytotoxic RAPTA-type complex with a strongly electron withdrawing arene ligand.
Egger AE; Hartinger CG; Renfrew AK; Dyson PJ
J Biol Inorg Chem; 2010 Aug; 15(6):919-27. PubMed ID: 20364440
[TBL] [Abstract][Full Text] [Related]
10. Ruthenium(ii) p-cymene complexes of a benzimidazole-based ligand capable of VEGFR2 inhibition: hydrolysis, reactivity and cytotoxicity studies.
Bhattacharyya S; Purkait K; Mukherjee A
Dalton Trans; 2017 Jul; 46(26):8539-8554. PubMed ID: 28638907
[TBL] [Abstract][Full Text] [Related]
11. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
Ruiz J; Vicente C; de Haro C; Bautista D
Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
[TBL] [Abstract][Full Text] [Related]
12. Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy.
Scolaro C; Chaplin AB; Hartinger CG; Bergamo A; Cocchietto M; Keppler BK; Sava G; Dyson PJ
Dalton Trans; 2007 Nov; (43):5065-72. PubMed ID: 17992291
[TBL] [Abstract][Full Text] [Related]
13. Arene control over thiolate to sulfinate oxidation in albumin by organometallic ruthenium anticancer complexes.
Hu W; Luo Q; Ma X; Wu K; Liu J; Chen Y; Xiong S; Wang J; Sadler PJ; Wang F
Chemistry; 2009 Jul; 15(27):6586-94. PubMed ID: 19533706
[TBL] [Abstract][Full Text] [Related]
14. Use of ion mobility mass spectrometry and a collision cross-section algorithm to study an organometallic ruthenium anticancer complex and its adducts with a DNA oligonucleotide.
Williams JP; Lough JA; Campuzano I; Richardson K; Sadler PJ
Rapid Commun Mass Spectrom; 2009 Nov; 23(22):3563-9. PubMed ID: 19844963
[TBL] [Abstract][Full Text] [Related]
15. Efficient oxidation of cysteine and glutathione catalyzed by a dinuclear areneruthenium trithiolato anticancer complex.
Giannini F; Süss-Fink G; Furrer J
Inorg Chem; 2011 Nov; 50(21):10552-4. PubMed ID: 21981265
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.
Scolaro C; Bergamo A; Brescacin L; Delfino R; Cocchietto M; Laurenczy G; Geldbach TJ; Sava G; Dyson PJ
J Med Chem; 2005 Jun; 48(12):4161-71. PubMed ID: 15943488
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the reactivity between a ruthenium hexacationic prism and biological ligands.
Paul LE; Therrien B; Furrer J
Inorg Chem; 2012 Jan; 51(2):1057-67. PubMed ID: 22221272
[TBL] [Abstract][Full Text] [Related]
18. Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms.
Vock CA; Ang WH; Scolaro C; Phillips AD; Lagopoulos L; Juillerat-Jeanneret L; Sava G; Scopelliti R; Dyson PJ
J Med Chem; 2007 May; 50(9):2166-75. PubMed ID: 17419606
[TBL] [Abstract][Full Text] [Related]
19. Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes.
van Rijt SH; Hebden AJ; Amaresekera T; Deeth RJ; Clarkson GJ; Parsons S; McGowan PC; Sadler PJ
J Med Chem; 2009 Dec; 52(23):7753-64. PubMed ID: 19791745
[TBL] [Abstract][Full Text] [Related]
20. Arene Ruthenium(II) Complexes with Phosphorous Ligands as Possible Anticancer Agents.
Biancalana L; Pampaloni G; Marchetti F
Chimia (Aarau); 2017 Sep; 71(9):573-579. PubMed ID: 30188287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
